PUBLICATIONS

Targeting immunosuppressive myeloid cells via implant-mediated slow release of small molecules to prevent glioblastoma recurrence
Y Kaiser, C Garris, E Marinari,  HS Kim, JH Oh, M Pedard, EA Halabi, MH Choi, S Parvanian, R Kohler, D Migliorini, R Weissleder
Nature Biomedical Engineering. 2025, (JCR 0.4%, IF 26.4)
[LINK]

A myeloid cell-targeted immunostimulant cocktail (MyTai) enhances cancer immunotherapy
HS Kim, G Simpson, J Carrothers, Y Nguyen, R Kohler, S Hong, S Cha, DH Kim, C Garris, R Weissleder
ACS Nano. 2025, (JCR 6.0%, IF 16.0)
[LINK] 

Fluorinated ribonucleocarbohydrate (RNC) nanoparticles allow ultraefficient mRNA delivery and protein expression in tumor-associated myeloid cells
HS Kim, G Simpson, F Fei, C Garris, R Weissleder
J. Am. Chem. Soc. 2025, 147, 14, 11766-11776 (JCR 4.8%, IF 15.6)
[LINK] 

Targeted SPP1 inhibition of tumor-associated myeloid cells effectively decreases tumor sizes
B Kartal, C Garris, HS Kim, R Kohler, J Carrothers, EA Halabi. Y Iwanoto, AG Goubet, Y Xie, P Wirapati, MJ Pittet, R Weissleder
Advanced Science. 2025, 12, 4 (JCR 7.6%, IF 14.3)
[LINK] 

Oxygenating respiratoid biosystem for therapeutic cell transplantation
SM Jang, CR Yoo, HS Kim, JY Kim, DY Lee
Nature Communications. 2024, 15, 9151 (JCR 5.6%, IF 14.7)
[LINK] 

Biocompatible and non-degradable microcapsule using ethylamine-bridged EGCG dimer for successful therapeutic cell transplantation
SM Jang, JB Lee, CR Yoo, HS Kim, KM Choi, JS Lee*, DY Lee*
Journal of Controlled Release. 2024. 373, 520-532 (JCR 3.9% IF 10.8)
[LINK] 

A non-lipid nucleic acid delivery vector with dendritic cell tropism and stimulation
HS Kim, EA Halabi, N Enbergs, R Kohler, C Garris, R Weissleder
Theranostics. 2024. 14, 2934-2945 (JCR 3.3%, IF 13.3)
[LINK] 

A Local Water Molecular-heating Strategy for Near-Infrared Long-lifetime Imaging-guided Photothermal Therapy of Glioblastoma
D Kang*, HS Kim*, S Han, Y Lee, YP Kim, DY Lee, J Lee
Nature Communications. 2023, 14, 2755 (JCR 2.263%, IF 17.694) (*denoted co-first author)
[LINK] 

Aurozyme: A Revolutionary Catalyst in Colitis, Switching Peroxidase-like to Catalase-like Activity
HS Kim*, S Lee*, DY Lee
Small. 2023, 19, 41, 2302331 (JCR 6.875%, IF 15.153)
[LINK] 

Inhibition of DAMP Actions in the Tumoral Microenvironment Using Lactoferrin-Glycyrrhizin Conjugate for Glioblastoma Therapy
HS Kim, SC Park, DY Lee
Biomaterials research. 2023, 27, 52 (JCR 3.093%, IF 15.863)
[LINK] 

Gastrointestinally absorbable lactoferrin-heparin conjugate with anti-angiogenic activity for treatment of brain tumor
HH Hwang*, HS Kim*, DY Lee
Journal of Controlled Release. 2023, 335,730-744 (JCR 4.317% IF 11.467) (*denoted co-first author)

[LINK] 

Nanoarchitectured Conjugates Targeting Angiogenesis: Investigating Heparin-Taurocholate Acid Conjugates (LHT7) as an Advanced Anti-Angiogenic Therapy for Brain Tumor Treatment
HS Kim*, JH Seol*, HH Hwang, DY Lee
Biomaterials Research.2023, 27, 89 (JCR 3.093%, IF 15.863)
[LINK] 

Photosensitizing deep-seated cancer cells with photoprotein-conjugated upconversion nanoparticles
SH Park, S Han, S Park, HS Kim, KM Kim, S Kim, DY Lee, J Lee, and YP Kim 

Journal of Nanobiotechnology. 2023, 21, 279 (JCR 8.861% IF 9.429)
[LINK] 

Milk protein-shelled gold nanoparticles with gastrointestinally active absorption for aurotherapy to brain tumor
HS Kim, SJ Lee, DY Lee
Bioactive Materials. 2022, 8, 35-48 (JCR 2.062% IF 14.593)
[LINK] 

DAMP-modulating nanoparticle for successful pancreatic islet and stem cell transplantation
SB Jang*, SM Jin*, HS Kim*, YY Jeong, SJ Lee, S Hahn, H Lee, HS Lee, JH Kim, and DY Lee
Biomaterials. 2022, 287 (JCR 3.093% IF 12.479) (*denoted co-first author)
[LINK] 

A novel therapeutic strategy of multimodal nanoconjugates for state-of-the-art brain tumor phototherapy
HS Kim, M Seo, TE Park, and DY Lee
Journal of Nanobiotechnology. 2022, 20:14 (JCR 5.00% IF 10.435)
[LINK] 

Nanozyme-based colorimetric biosensor with a systemic quantification algorithm for noninvasive glucose monitoring
HJ Jeon, HS Kim, E Chung, DY Lee
Theranostics. 2022, 12,14, 6308-6338 (JCR 6.475% IF 11.556)
[LINK]